Related by context. All words. (Click for frequent words.) 85 SFAS #R 78 FAS#R 78 FAS# R 78 No. #R 76 SFAS 73 SFAS No. 73 FSP APB #-# 72 EITF #-# [001] 71 ASC #-# 71 No. #R Share 71 Statement #R 71 SFAS#R 71 FASB #R 70 compensation expense 69 EITF #-# [002] 69 SFAS# R 69 FSP EITF #-#-# [002] 68 Based Compensation 68 No. #R SFAS 68 FAS #R Share 67 SFAS No.#R 67 adopting SFAS #R 66 adopted SFAS #R 66 FASB Interpretation No. 66 SFAS No.# 66 FASB Statement 66 SFAS #R Share 65 ASC Topic 65 FASB ASC 65 option expensing 65 CICA Handbook section 65 adopting SFAS 64 FASB Statement #R 64 APB# 64 CICA Handbook Section 64 FAS #R Accounting 64 adopted SFAS 64 FASB Statement No. 63 FASB ASC #-# 63 FASB ASC Topic 63 FSP FAS #-# 63 #R Share Based 63 Compensation Expense 63 Accounting Standards Codification 62 LIFO accounting 62 ASC Subtopic #-# 62 expensing 62 Based Compensation Expense 62 AcG 62 FSP #-# 62 CICA Accounting Guideline 61 CICA Section 61 Based Payment SFAS 61 Business Combinations 61 Position APB #-# 61 retrospectively adjusted 60 Conditional Asset 60 adopting FAS #R 60 IFRS2 60 Payment SFAS #R 60 #R Share 59 FIN #R Consolidation 59 Accounting Standards Codification ASC 59 Payment FAS #R 59 GAAP 59 ASC# 58 Position EITF #-#-# 58 amortization expense 58 Accounting Guideline 58 Asset Retirement Obligations 58 Pro forma adjustments 58 contingently convertible debt 58 applied prospectively 58 accelerated vesting 58 Adjusted EBITDA excludes 58 DAC unlock 58 FIN #R 57 Hedging Relationships 57 FSP EITF #-#-# [001] 57 EITF #-#-# 57 Incentive Compensation Plan 57 FAS# [001] 57 FASB Accounting Standards Codification 57 EITF Topic D 57 Compensation Expenses 57 adopting FIN 57 No. #R FAS 57 Adjusted Pro Forma 56 debt extinguishments 56 dilutive securities 56 Adjusted diluted 56 Handbook Sections 56 Accounting Principles 56 acquired intangible assets 56 FASB Staff 56 unvested 56 QUALCOMM Strategic Initiatives 56 Visa indemnification 56 ASC Topic #-# 56 FAS #-# 56 non recurring 56 stock basedcompensation 56 SFAS# 56 Contingently Convertible Debt 56 Statement #R Share 56 Adjusted EBTIDA 56 Stock Compensation Expense 56 FASB EITF 56 FAS CAS pension 56 LIFO inventory valuation 56 intangible impairment 55 exclude noncash 55 adopted FASB Statement 55 Non GAAP diluted 55 EITF Issue No. 55 purchased intangible assets 55 NETg acquisition 55 contingently issuable shares 55 unvested restricted stock 55 Retirement Obligations 55 ASC #-#-# 55 nonGAAP 55 Pro forma EBITDA 55 Derivative Instruments 55 Variable Interest Entities 55 Option Grants 55 - -Frode Johnsen 55 Non GAAP net 55 FIFO method 55 intangible assets impairment 55 Stock Incentive Plan 55 Pro forma EPS 55 operatingincome 54 GAAP Generally Accepted 54 INIF 54 addback 54 Oxy ER 54 Equity Incentive Plan 54 Pro forma diluted 54 Significant Items 54 Subtopic #-# 54 Normalized EBITDA 54 unrealized derivative 54 Goodwill Impairment 54 expensed 54 -triseries 54 per dilutedshare 54 noncash amortization 54 netincome 54 adopted FSP APB 54 FSP APB# 1 54 STOCK BASED COMPENSATION 54 LPT Agreement 54 Determining Whether 54 IAROC 54 Normalized EPS 54 IFRS 54 Modified EBITDA 54 NOL utilization 54 Lodging Reported EBITDA 54 FSP AUG AIR 54 APB Opinion No. 54 LIFO method 54 GAAP EPS 54 Adjusted Diluted EPS 54 Financial Instruments Disclosures 54 Non GAAP EPS 54 non GAAP 53 Core FFO 53 - Non GAAP [031] 53 intangibles impairment 53 Recent Accounting Pronouncements 53 unconsolidated investee 53 FAS CAS Pension 53 No.#R 53 Qualcomm Strategic Initiatives 53 Non GAAP adjusted EBITDA 53 Contingently Convertible Instruments 53 Consolidated Adjusted EBITDA 53 retroactive restatement 53 Pro forma net 53 unrealized derivative gain 53 Financial Accounting Standards 53 Handbook Section 53 IFRS IASB 53 FIFO inventory 53 Neurogen stockholders 53 Projected FFO 53 Unlevered Cash Flow 53 adopting IFRS 53 OTTI charges 53 FAS #R expense 53 restatement 53 depreciation accretion 53 AIFRS 53 earnings pershare 53 Accounting Guideline AcG 53 Dilutive securities 53 pension curtailment 53 DAC offsets 53 No. #R Consolidation 53 GSCT program 52 diluted EPS 52 NYSE Rule #A.# 52 Accounting Policies 52 valuation methodologies 52 - Non GAAP [017] 52 Stockholder Rights Plan 52 SFAS No.# Accounting 52 Diluted EPS attributable 52 Acquired Intangible Assets 52 NOL carryforwards 52 LIFO adjustment 52 FASB Interpretation 52 Asset Retirement Obligation 52 early extinguishments 52 - Non Shane Germann 52 Hedging Relationships AcG 52 dacetuzumab collaboration 52 noncash 52 Adjusted EPS 52 NASDAQ Marketplace Rule 52 valuation allowance 52 pretax goodwill impairment 52 EITF 52 derivative instruments 52 Non GAAP 52 pro forma adjusted EBITDA 52 contingently convertible securities 52 Non GAAP Diluted EPS 52 CGAAP 52 accretion DD & 52 depreciation amortization depletion 52 Adjusted OIBDA excludes 52 Surface Specialties acquisition 52 Consolidated OIBDA 52 accrual 52 Standard #R Share 52 temporary impairments 52 intangibles amortization 52 - Non GAAP [009] 52 EBITDA Calculation 52 acquired intangibles 52 f Represents 52 Asset Impairment 52 commodity derivative instruments 52 Successor Period 52 - - Non GAAP [006] 52 CICA Handbook 52 Non GAAP Adjusted 52 Hedging Activities 52 OTTI charge 52 Generally Accepted Accounting Principles 52 Board FASB Accounting 52 c Relates 52 carryforwards 52 DTR #.#.#R 52 Pro Forma EBITDA 52 purchased intangibles 52 FIFO EBITDA 52 Adjusted EBITDAX 52 Depreciation Amortization 52 Unconsolidated Investments 52 Items affecting comparability 52 Assuming Dilution 52 Non GAAP Proforma 52 DNOI 51 HKAS 51 derivative liabilities 51 Variable Interest Entities VIEs 51 hedge ineffectiveness 51 retrospectively restated 51 Non Controlling Interests 51 Restricted Share 51 Certain comparative 51 nonroutine income 51 c Consists 51 items affecting comparability 51 COSO framework 51 #.# perdiluted 51 Pro forma 51 nonrecurring 51 Diluted Earnings 51 DiaMed acquisition 51 accrual reversal 51 Diluted EPS 51 retroactively restated 51 RSU Plan 51 FASB Emerging 51 early extinguishment 51 Expensing 51 Items impacting comparability 51 Accounting Standards Codification Topic 51 Pro Forma Revenues 51 EITF Issue 51 intangible amortization 51 AASB 51 uncollectible accounts receivable 51 Than Temporary Impairments 51 - Adjusted EBITDA [006] 51 Reclassifications 51 Adjusted Earnings Per 51 excludes unrealized gains 51 temporary impairments OTTI 51 Adjusted Earnings 51 - Non GHanno Coetzee 51 depreciation amortization accretion 51 Termination Benefits 51 reclassed 51 goodwill impairment 51 amortizable intangible assets 51 Unizan merger 51 d Represents 51 debt extinguishment 51 Adjusted EBITDA 51 - Adjusted [016] 51 Cumulative Effect 51 LIFO 51 noncash impairments 51 Impairment Losses 51 OPEB expense 51 antidilutive 51 adjusted EBITDAS 51 non gaap 50 QSI segment certain 50 EBITDAO 50 Black Scholes Merton 50 economically defeasing 50 derivative instrument 50 Adjusted FIFO EBITDA 50 Adjusted EBITDAS 50 Entity Own 50 Pro forma adjusted EBITDA 50 -Winchester Thurston 50 noninterest expense decreased 50 valuation adjustments 50 Adjusted FFO 50 Proforma adjustments 50 Collaborative Arrangements 50 - Nowww.bjc.psu.edu 50 MTM adjustments 50 profitsharing 50 Appreciation Rights 50 Accounting Principle 50 accounting pronouncements 50 Income Taxes 50 IFRS IFRS 50 b Reflects 50 unrealized appreciation 50 financialstatements 50 Adjusted Net 50 Adjusted Non GAAP 50 Acquisition Related 50 Reconciling Items 50 Impairment Charges 50 intangible assets 50 EBITDAS EBITDA 50 unrealized derivative gains 50 disqualifying dispositions 50 Equity Investees 50 Normalized FFO 50 NASDAQ Listing Rule 50 NAREIT definition 50 Certain reclassifications 50 inventories revalued 50 unrealized gains losses 50 NON GAAP 50 Accounting Bulletin 50 Pro Forma EPS 50 Contingent Consideration 50 Accelerated vesting 50 Fee Earning Assets 50 income teb 50 depreciation noncash 50 accretion expense 50 Capital Disclosures 50 Embedded Derivatives 50 unrealized depreciation 50 Comdisco Holding Company 50 adjusted EBITDAR 50 unallocated expenses 50 * Reclassified 50 CICA issued 50 Derivative Liabilities 50 intangible asset impairments 50 Partial Cash 50 IFRSs 50 fiscal# 50 Pro forma Adjusted EBITDA 50 Non Recurring 50 invoiced shipment 50 nonrecurring items 50 Tikcro holdings 50 = Loss [004] 50 Unvested 50 deductible goodwill impairment 50 Regulation FD 50 share assuming dilution 50 Adjustments Restructuring 50 Long Term Incentive Plan 50 QUALCOMM pro forma 50 nonoperating expense 50 Non GAAP Adjustments 50 - Adjusted [034] 50 excludes noncash 50 Adjusted EBT 50 Restatement 50 LIFO adjustments 50 Board FASB Interpretation 50 b Excludes 49 postretirement benefit 49 Adjusted OIBDA 49 - - Net [047] 49 unamortized financing 49 EMEA Subsidiaries 49 Timeshare segment 49 - Adjusted [019] 49 Recurring FFO 49 Non GAAP Adjusted EBITDA 49 USGAAP 49 -Sheikh Mohammed Godolphin 49 units RSUs 49 Adjust ments 49 = NetSao Pedro 49 Comparable Basis 49 - Adjusted [022] 49 - Non GAAP [025] 49 capitalizable 49 IAS IFRS 49 loss NOL carryforward 49 NAREIT FFO 49 FRS# 49 ended December# 49 - Adjusted [006] 49 - Non GAAP [018] 49 Adjusted Gross Profit 49 FAS# [003] 49 Predecessor Period 49 unvested options 49 Consolidated adjusted EBITDA 49 Normalised earnings 49 - - NetMarigot Bay r 49 deferred compensation 49 Note Certain reclassifications 49 valuation allowances 49 Payment #R 49 Task Force EITF 49 - Adjusted [028] 49 earnout payments 49 Remainco 49 No. AUG AIR 49 = Basic earnings [010] 49 covenant calculations 49 Diluted earnings 49 LTM Adjusted EBITDA 49 Gross Addition CPGA 49 LIFO inventory 49 Adjusted Operating Expenses 49 Dilutive 49 Copano commodity 49 IFRIC 49 Noncontrolling Interest 49 Non GAAP Basis 49 - Adjusted [010] 49 DEPS 49 ACLARA 49 aftertax charge 49 CIM Mineral Exploration 49 Non IFRS 49 - Non GAAP [027] 49 NASDAQ Listing Rules 49 #.#/diluted share 49 QSI segment 49 Extinguishment 49 share excluding AOCI 49 nonoperating income 49 infrequently occurring 49 Regulation SK 49 Incentive Plan 49 adopted CICA Handbook 49 = Earnings [026] 49 Intangibles Goodwill 49 -Artunduaga 49 Option Expense 49 Contingent Value Rights 49 - Adjusted [017] 49 Restated 49 dilutive antidilutive effects 49 = Adjusted [008] 49 applies prospectively 49 Adjustment Expenses 49 receive nonforfeitable dividends 49 earnouts 49 unvested stock 49 excluding QSI 49 diluted share 49 unallocated corporate 49 Incurred 49 calculating FFO 49 Intangibles amortization 49 credit carryforwards 49 Non GAAP adjustments 49 NON CASH EXPENSES 49 vesting provisions 49 EBITDA EBITDAM EBITDAR 49 DAC unlocking 49 excluding BIBP 49 Black Scholes 49 internally evaluates 48 standardized distributable cash 48 Introductory teaser rates 48 - Loss [020] 48 Employment Inducement Award 48 Inducement Equity Incentive Plan 48 Mayne Pharma intangible assets 48 -Laemmle Music 48 - Adjusted [031] 48 Emerging Issues 48 nonrecurring expenses 48 OREO valuation 48 Noncash 48 Fully diluted earnings 48 AJCA 48 FSP FAS 48 Rule #a 8 48 rebased amounts 48 Income Tax Expense 48 - Aijaz Hussain 48 RSUs 48 PGP Acquisition 48 GAAP Adj 48 Repurchase Program 48 - -Belusko 48 Inc. NASDAQ EVVV 48 Business Combinations SFAS 48 Payments SFAS #R 48 Net Loss Attributable 48 discount accretion 48 depreciation depletion amortization 48 remeasurement 48 LIFO inventory decrement 48 - - Net [003] 48 postemployment benefits 48 Excluding Unusual Items 48 Excludes amortization 48 Sarbanes Oxley compliance 48 retroactive reinstatement 48 ended September# 48 Gaap 48 Arana Therapeutics Limited 48 c Represents 48 American Jobs Creation 48 Reimbursable Expenses 48 = ReconciliationHyperesponse 48 unrealized gains 48 Income Loss Per Share 48 - Adjusted [011] 48 IAS# [002] 48 DSUs 48 Reporting Standards 48 goodwill impairment charge 48 Inducement Plan 48 identifiable intangible assets 48 EBITDAS 48 Excluding goodwill impairment 48 OTTI 48 reinsurance commutations 48 INOVA Geophysical 48 Accretion expense 48 Total Capitalization 48 Non GAAP Measure 48 MA PFFS 48 Omnibus Incentive Plan 48 unamortized deferred 48 CICA Handbook Sections 48 = Diluted [019] 48 - - [060] 48 identifiable intangibles 48 TWACS NG software 48 Dropdown Predecessor 48 Guidance Guidance 48 Deductions depreciation 48 Intangible Assets 48 Assumed provision 48 - Adjusted [024] 48 noncash accounting 48 MDP Transaction 48 interim condensed consolidated 48 Depletion Depreciation 48 b Represents 48 millioncompared 48 Concur excludes 48 pershare 48 - Adjusted [012] 48 Items excluded 48 - Non GAAP [002] 48 Earnings Per Diluted 48 Rev. Proc 48 amortizable 48 Accounting Pronouncements 48 excludes amortization 48 Taxable equivalent 48 - -freefall parachute 48 LIFO provision 48 Depreciation Depletion 48 invoiced shipments 48 Fourth Quarter Earnings Per 48 EBIAT 48 Huarun minority interest 48 compensation accruals 48 MFFO 48 - Adjusted EBITDA [002] 48 ATCF 48 Qtr Qtr 48 Offerors Commercial applies 48 excluding AOCI 48 amortization 48 Instruments Granted 48 noncash goodwill impairment 48 MHPAEA 48 Nasdaq Listing Requirements 48 Before Unusual Items 48 excludes depreciation 48 La.Code Crim.P. art 48 - AdjusETON 48 fuel CASM 47 Fair Value Measurements 47 PMPS brand 47 TEB adjustment 47 Adjusted Ebitda 47 Per Fully Diluted 47 Convertible Debt 47 FASB Codification 47 WESTWOOD ONE INC. SUPPLEMENTAL 47 = Net [018] 47 #.#per diluted 47 Issuer Amended 47 unabsorbed fixed manufacturing 47 - - Non GAAP [007] 47 AOCI 47 IPSAS 47 asset valuation allowance 47 Restructuring asset impairments 47 Valhi stockholders 47 dilutive effect 47 Performance Incentive Plan 47 reconciles Adjusted EBITDA 47 Share Repurchase Plan 47 incurs amortization 47 Diluted Earnings Per Share 47 Fully Diluted Earnings Per 47 BlackRock MLIM transaction 47 unamortized portion 47 Standardized Distributable Cash 47 operating loss carryforwards 47 auditor attestation 47 Nasdaq Deficiency Notice 47 FDIC indemnification 47 VSOE 47 doubtful accounts receivable 47 actuarially determined 47 Items Affecting Comparability 47 GAAP Diluted EPS 47 Adjusted Margin 47 = Adjusted [002] 47 Nasdaq Notice Regarding 47 Levered Free Cash Flow 47 COF FINANCIAL & 47 Goodwill Impairment Charge 47 Discretionary cash 47 CRIC shareholders 47 unfavorable variance 47 UNUSUAL ITEMS 47 pro forma 47 Partnered Brands segment 47 EUR #,# Mio 47 - Non GAAPalanquero base 47 Staff Position FSP 47 Specified Items 47 STOCK BASED COMPENSATION EXPENSE 47 Items Impacting Comparability 47 Variable Interest Entities FIN 47 CICA Emerging 47 temporary impairment OTTI 47 - Non GAAP [019] 47 Adjusted OIBA 47 Restruct 47 Pro Forma Net 47 Cellu Tissue stockholders 47 LAE reserves 47 f Reflects 47 - - [073] 47 Nonrecurring 47 Equinix excludes 47 Regains NASDAQ 47 EBDDT 47 Act AJCA 47 adopted FASB Interpretation 47 CICA handbook 47 - Non GAAP [004] 47 Annual Incentive Plan 47 - Adjusted [025] 47 MEP Joint Venture 47 - Non GAAP [007] 47 diluted weighted 47 adjusted EBITDA 47 Regulation FD Disclosure 47 Discontinued Lines 47 Vyvx Advertising Distribution 47 CFFO 47 depletion depreciation 47 - Adjusted EBITDA [001] 47 unrealized hedging 47 - - Diluted [005] 47 asset impairment 47 Than Temporary Impairment 47 Restatements 47 Restructuring Charges 47 -DD2 47 Corporate Overhead 47 Regulation G 47 FAS 47 intangible impairments 47 reclass 47 unamortized discount 47 GLJ Report 47 = Earnings [007] 47 Business.com Acquisition 47 BioMarin Genzyme LLC 47 NON GAAP NET INCOME 47 Generally Accepted Auditing Standards 47 - - Adjusted EBITDA [001] 47 Inducement Awards 47 - Non GAAP [003] 47 Stock Option Vesting 47 Debt Extinguishment 47 -CSMMU 47 accounting principles 47 share repurchase authorizations 47 EBITDAX 47 Contingent Value Right 47 minimally dilutive 47 Related Costs 47 - - Net [035] 47 - - [019] 47 ESPP 47 Stock Buyback Program 47 OIBA 47 Senior Convertible Notes 47 Unconsolidated Joint Ventures 47 Fully diluted EPS 47 PMCS symbol 47 Promotions.com subsidiary 47 wife Krementz 47 GASB Statement No. 47 affecting comparability 47 graded vesting 47 Employees APB 47 accompanying unaudited consolidated 47 Concession Arrangements 47 VERISIGN INC. AND SUBSIDIARIES 47 Weighted Weighted Average 47 noncash goodwill 47 - Non GAAPsmokable form 47 -him.I 47 Inc. OTC CDCO 47 excluding goodwill impairment 47 AOCL 47 assuming dilution 47 - - Non GAAP [001] 47 months endedSeptember 47 Income Tax Provision 47 meaningful supplemental 47 - Adjusted EBITDA [004] 47 Noninterest expense decreased 47 #.#/BOE [002] 47 Before Cumulative Effect 47 - Non GAAP [028] 46 IFRS changeover 46 principles GAAP 46 AVONEX multiple sclerosis 46 noninterest expense totaled 46 continuingoperations 46 EPS Guidance 46 Unearned compensation restricted 46 PNOI 46 ADJUSTED EBITDA 46 Asset Impairment Charges 46 -By DON HUNTER 46 Operating Expenses Compensation 46 foreign currency remeasurement 46 FFO Per Share 46 - Adjusted [014] 46 Commencement Date 46 Grandfathered Plans 46 non GAAP1 46 Convertible Subordinated Debt 46 nausea superficial edema 46 SIFT Rules 46 unamortized 46 EBDT 46 substantively enacted 46 accretable 46 unabsorbed manufacturing 46 Accounting Standards 46 intersegment eliminations 46 Pro Forma Adjusted EBITDA 46 nine monthsended 46 Accelerated Share Repurchase 46 MFRS 46 Option Scheme 46 c Excludes 46 NONRECURRING ITEMS 1 46 LIFO inventory accounting 46 pretax noncash 46 discontinued operations 46 NASDAQ Listing 46 Standardized distributable cash 46 = Earnings [019] 46 Annualized Adjusted EBITDA 46 Stock Repurchase Plan 46 Reports Inducement Grants 46 depreciation amortization impairment 46 Restructuring Charge 46 - Non GAAP [015] 46 nondeductible portion 46 Nasdaq Listing Rules 46 #,#,# #,#,# = [008] 46 quarterended 46 Plan ESPP 46 Nasdaq Marketplace Rule 46 aftertax 46 SurfControl deferred revenue 46 calculating SS NOI 46 REITs FFO 46 Marketplace Rules 46 unrealized MTM 46 Adjusted Operating Margin 46 Form 8K 46 Contingent consideration 46 = Diluted [014] 46 Chartered Accountants CICA Handbook 46 FAR #.#-# Instructions 46 calculates FFO 46 Comparable FFO 46 Stock Repurchase Program 46 = Diluted [015] 46 MMSEA 46 Benefit Expense Ratio 46 SMTEK 46 amortized cost 46 comparability 46 mildly dilutive 46 Accounting Principles GAAP 46 Brooks Eckerd acquisition 46 ticker ADI 46 SEC Regulation SX 46 Realizable Value 46 accrual reversals 46 excluding depreciation amortization 46 SUMMIT FINANCIAL GROUP INC. 46 tables summarize 46 Second Quarter Highlights 46 Michael Crooch 46 GAAP EARNINGS 46 extinguishment 46 undesignated hedges 46 Purchased Intangible Assets 46 = Non GAAP [003] 46 accruals 46 normalized FFO guidance 46 per mcfe 46 intangible asset 46 Standards Codification ASC 46 #,# =Jaegle 46 Diluted FFO 46 QSPEs 46 No. EITF #-#-# 46 NOLs 46 Consolidated EBITDAR 46 Quality Process Improvement 46 OSIs 46 DPAC amortization 46 Impairment Charge 46 Reporting Standards IFRS 46 Selected GAAP Measures 46 FFO FFO 46 Qtr Qtr Year 46 intercompany eliminations 46 - Pro forma [003] 46 MR Civ 46 LTIP 46 Acquired Intangibles 46 enhances comparability 46 Cumulative effect 46 Diluted Earnings Loss Per 46 MDS Proteomics 46 b Relates 46 -MarketPlace# TM 46 Comparable EBITDA 46 QCR HOLDINGS INC. CONSOLIDATED 46 ยง #A [003] 46 CIM Definition Standards 46 = Non GAAP [014] 46 unaudited pro forma 46 unaudited consolidated balance sheets 46 - - Net [055] 46 nonvested 46 noncontrolling interests 46 d Reflects 46 IFRS IAS 46 MFB Corp 46 Non GAAP Pro Forma 46 -David# 46 EBITDAC 46 vesting 46 Banks.com s 46 thequarter ended 46 EPIL III 46 golden parachute arrangements 46 Asset Impairment Charge 46 condensed consolidated interim 46 severance accruals 46 = Weighted average [003] 46 Annual Audited Consolidated 46 Nortel remedial 46 AutoZone repurchased 46 HealthStream Learning 46 = Basic [035] 46 Pro Forma Operating 46 Currency Translation 46 #g# 2 46 - TOTAL LIABILITIES AND [013] 46 MMLP Quarterly Report 46 unvested restricted shares 46 materially misstated 46 Inducement Stock 46 EFFECT OF FOREIGN CURRENCY 46 Diluted EPS Diluted 46 = Non GAAP [005] 46 -Senanu 46 PIXMA MX# Office 46 Reported ments 46 impacting comparability 46 c Calculated 46 Proforma EBITDA 46 SEBI ICDR Regulations 46 Adjusted EBITDA1 46 CHANGES IN ACCOUNTING POLICIES 46 Diluted Share 46 Non GAAP Disclosures 46 - Net [030] 46 IBNR reserve 46 SEK -#.# -#.# [002] 46 Financial Reporting Standards 46 prioryear 46 - -Majority Whip Roy Blunt 46 - - Non GAAPHawai'i Paroling Authority 46 EBITD 46 QUARTER ENDED YEAR ENDED 46 income allocable 46 Income Taxes Allocable 46 FFOM 46 currency remeasurement 46 Position FSP No. 46 Gold Eq 46 ORACLE CORPORATION Q1 FISCAL 46 normalized FFO 46 -Gottron 46 CIP FENOFIBRATE 46 INCOME STATEMENT UNAUDITED 46 - Adjusted [013] 46 Convertible Notes tendered 46 Interest Income Expense 46 NOL Protective Measures 46 CarbonNeutral Protocol 46 -Kunati 46 condensed consolidated 46 Position FSP 46 Non Controlling Interest 46 Vishay stockholders 46 - - Nforecaddie 46 VaxGen stockholders 46 PER DILUTED SHARE 46 = Earnings [013] 46 Debt extinguishments 46 = Net [019] 46 = Weighted average [026] 46 - - [084] 46 OPANA franchise 46 Debt Settlement Agreements 46 = Diluted [027] 46 Pharmacia Monsanto 46 restatements 46 Adjusted EBITDA Adjusted 46 -FORWARD LOOKING STATEMENTS CONTAINED 46 #,# =Bill Duemling 46 USD#.#m USD#.# [002] 46 Significant Accounting Policies